Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 3/20 | 0.46 |
| ▸ | ST6GAL1 | P15907 | 11/20 | 0.45 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.45 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.41 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18495198 | 1.00 | P2RY2 (0.46) | P2RY2ST6GAL1P2RY4P2RY6TSHR | |
| SCHEMBL20068332 | 0.92 | P2RY2 (0.43) | P2RY2ST6GAL1P2RY4P2RY6TSHR | |
| SCHEMBL24169755 | 0.90 | P2RY2 (0.51) | P2RY2ST6GAL1P2RY4P2RY6TSHR | |
| SCHEMBL24170210 | 0.90 | P2RY2 (0.51) | P2RY2ST6GAL1P2RY4P2RY6TSHR | |
| SCHEMBL20180415 | 0.90 | ST6GAL1 (0.43) | P2RY2ST6GAL1P2RY4P2RY6TSHR | |
| SCHEMBL16093276 | 0.89 | ST6GAL1 (0.47) | P2RY2ST6GAL1P2RY4P2RY6TSHR | |
| SCHEMBL12495844 | 0.89 | ST6GAL1 (0.47) | P2RY2ST6GAL1P2RY4P2RY6TSHR | |
| SCHEMBL17021020 | 0.89 | ST6GAL1 (0.47) | P2RY2ST6GAL1P2RY4P2RY6TSHR | |
| SCHEMBL18495200 | 0.89 | ST6GAL1 (0.47) | P2RY2ST6GAL1P2RY4P2RY6TSHR | |
| SCHEMBL10044129 | 0.89 | ST6GAL1 (0.47) | P2RY2ST6GAL1P2RY4P2RY6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170096655-A1 | COAGULATION FACTOR VII POLYPEPTIDES | NOVO NORDISK HEALTHCARE AG (CH) | 2017-04-06 | — | — | US | disclosed |
| US-20160024487-A1 | THROMBIN SENSITIVE COAGULATION FACTOR X MOLECULES | NOVO NORDISK A/S (DK) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096655-A1 | COAGULATION FACTOR VII POLYPEPTIDES | F7, F13B, HABP2 | P2RY2 4167/4885ST6GAL1 524/4885P2RY4 3943/4885 |
| US-20160024487-A1 | THROMBIN SENSITIVE COAGULATION FACTOR X MOLECULES | F11, F5, F13B | P2RY2 4406/4885ST6GAL1 1027/4885P2RY4 4376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.